Undisclosed BiMA based macrophage engager
/ King Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
BiMA, a Bi-Specific Monocyte Activator, as a First-in-Class Macrophage Engager Driving Cancer-Selective Phagocytosis
(SITC 2026)
- No abstract available
Bispecific • Oncology
1 to 1
Of
1
Go to page
1